Your browser doesn't support javascript.
loading
Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors.
Hosaka, Kayoko; Yang, Yunlong; Seki, Takahiro; Du, Qiqiao; Jing, Xu; He, Xingkang; Wu, Jieyu; Zhang, Yin; Morikawa, Hiromasa; Nakamura, Masaki; Scherzer, Martin; Sun, Xiaoting; Xu, Yuanfu; Cheng, Tao; Li, Xuri; Liu, Xialin; Li, Qi; Liu, Yizhi; Hong, An; Chen, Yuguo; Cao, Yihai.
Afiliação
  • Hosaka K; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden.
  • Yang Y; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden.
  • Seki T; Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
  • Du Q; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden.
  • Jing X; Kagoshima University Graduate School of Medical and Dental Sciences, 890-8520, Kagoshima, Japan.
  • He X; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden.
  • Wu J; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden.
  • Zhang Y; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, 250033, China.
  • Morikawa H; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden.
  • Nakamura M; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden.
  • Scherzer M; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden.
  • Sun X; Medicine and Pharmacy Research Center, Binzhou Medical University, Yantai, 264003, Shandong, China.
  • Xu Y; Unit of Computational Medicine, Department of Medicine, Center for Molecular Medicine, Karolinska Institute, 171 76, Stockholm, Sweden.
  • Cheng T; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden.
  • Li X; Department of Urology, The University of Tokyo Hospital 7-3-1, Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan.
  • Liu X; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden.
  • Li Q; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden.
  • Liu Y; Department of Medical Oncology and Cancer Institute, Shuguang Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
  • Hong A; The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Chen Y; The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Cao Y; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, 510060, Guangdong, China.
Nat Commun ; 11(1): 3704, 2020 07 24.
Article em En | MEDLINE | ID: mdl-32709869

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator de Crescimento Derivado de Plaquetas / Fator 2 de Crescimento de Fibroblastos / Inibidores da Angiogênese / Fator A de Crescimento do Endotélio Vascular / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator de Crescimento Derivado de Plaquetas / Fator 2 de Crescimento de Fibroblastos / Inibidores da Angiogênese / Fator A de Crescimento do Endotélio Vascular / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article